Boehringer

BearingPoint client success story: Boehringer Ingelheim increases data accuracy by leveraging robotic process automation

Retrieved on: 
Thursday, May 6, 2021
Software, Pharmaceutical, Health, Consulting, Data management, Professional services, Technology, Other Health, BearingPoint, UiPath, Boehringer Ingelheim, Boehringer, Ingelheim am Rhein, Business process management, Information technology, Software, Companies

Boehringer Ingelheim now has a more efficient material verification process, with an automated execution and the lowest risk of human errors.\nManagement and technology consultancy BearingPoint worked with Boehringer Ingelheim in gathering data from each manual step involved in the storage process by using UiPath\xe2\x80\x99s Task Capture\xc2\xae.

Key Points: 
  • Boehringer Ingelheim now has a more efficient material verification process, with an automated execution and the lowest risk of human errors.\nManagement and technology consultancy BearingPoint worked with Boehringer Ingelheim in gathering data from each manual step involved in the storage process by using UiPath\xe2\x80\x99s Task Capture\xc2\xae.
  • A Process Definition Document was created, with a detailed As-Is and To-Be process description.
  • BearingPoint transferred the current manual methodology into a master file template, making it easy to adapt to potential changes, and providing data for a bot to read.
  • The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success.

Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge

Retrieved on: 
Wednesday, May 5, 2021
Boehringer, Cannata, Ingelheim am Rhein, Bernie, Breathless, Germany, Names

The collective public votes will be tallied together and count as one vote; each of the judges will also cast one vote.

Key Points: 
  • The collective public votes will be tallied together and count as one vote; each of the judges will also cast one vote.
  • Individuals can vote by viewing the lyric submissions on Bernie Williams\' and Boehringer Ingelheim\'s social media channels.
  • If the voting process results in a tie, Bernie Williams and Emmy-award winning music producerEren Cannata will collaborate to determine the winning lyrics.\n"I\'m truly touched by the number of outstanding entries we\'ve received and very honored to be joined by such talented judges to help select the winner of the Breathless Ballad Challenge," said Bernie Williams.
  • "This effort is personally important to me, and I am grateful to be able to honor my dad and everyone affected by IPF through music.

Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands Scientific Advisory Team

Retrieved on: 
Tuesday, April 27, 2021
Branches of biology, Psychiatry, Psychiatric diagnosis, Neuroscience, Cognitive disorders, Learning disabilities, Abnormal psychology, Dementia, Alzheimer's disease, Boehringer Ingelheim, Boehringer, Serotonin

As a Key Opinion Leader studying Alzheimer\xe2\x80\x99s disease, Krista\xe2\x80\x99s work focuses on cognitive and neuropsychiatric symptoms associated with dementia.

Key Points: 
  • As a Key Opinion Leader studying Alzheimer\xe2\x80\x99s disease, Krista\xe2\x80\x99s work focuses on cognitive and neuropsychiatric symptoms associated with dementia.
  • Previously, Dr. Duan spent more than 20 years at Boehringer Ingelheim (Canada) Ltd. in roles of increasing responsibility, most recently as Director, Preclinical ADMEPK/Pharmacology.
  • Before joining Bright Minds, Mr. Grizzle was a successful consultant, advising clients across these critical domains and helping them achieve successful outcomes.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.

Inflammasome Therapeutics’ Kamuvudines May Be Answer to Preventing Blindness in Aging Population

Retrieved on: 
Monday, April 19, 2021
Other Consumer, Women, Other Health, Seniors, Other Science, Pharmaceutical, Other Technology, MEN, Research, Optical, Family, Consumer, Science, Technology, General Health, Biotechnology, AIDS, Health, Reverse-transcriptase inhibitor, Boehringer Ingelheim, Inflammasome, Boehringer, Economy of Germany, Germany

NRTIs have been in use for more than 25 years to treat HIV and Hepatitis B infections.

Key Points: 
  • NRTIs have been in use for more than 25 years to treat HIV and Hepatitis B infections.
  • Kamuvudines are slightly modified forms of NRTIs designed to avoid their toxicity, but have the same inflammasome inhibiting activity.
  • Paul Ashton, President and CEO of Inflammasome Therapeutics, the company commercially developing Kamuvudines for treatment of inflammasome-activated diseases, noted that GA currently has no approved treatment and ultimately results in blindness.
  • The company currently has collaboration agreements with Boehringer Ingelheim and the Bill & Melinda Gates Foundation.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210419005273/en/\n'

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Retrieved on: 
Wednesday, April 14, 2021
Research, Clinical trials, Biotechnology, Health, University, Pharmaceutical, Science, Education, Oncology, Academic journals, Boehringer Ingelheim, KRAS, MD Anderson Cancer Center, Boehringer, Cancers, Publications, Economy of Germany

Under the new agreement, joint research will continue for five additional years.\n\xe2\x80\x9cOur collaboration with MD Anderson strengthens our determination to find solutions for the most difficult-to-treat cancers, and this latest commitment marks an important step forward, especially in our holistic KRAS program,\xe2\x80\x9d said Norbert Kraut, Ph.D., Head of Global Cancer Research at Boehringer Ingelheim.

Key Points: 
  • Under the new agreement, joint research will continue for five additional years.\n\xe2\x80\x9cOur collaboration with MD Anderson strengthens our determination to find solutions for the most difficult-to-treat cancers, and this latest commitment marks an important step forward, especially in our holistic KRAS program,\xe2\x80\x9d said Norbert Kraut, Ph.D., Head of Global Cancer Research at Boehringer Ingelheim.
  • \xe2\x80\x9cWe are delighted to extend our collaboration with MD Anderson.
  • Boehringer Ingelheim is pursuing a comprehensive mutant KRAS-directed effort with multiple programs expected to enter the VRDC with MD Anderson.\n\xe2\x80\x9cWe are proud to expand our work with Boehringer Ingelheim in a very exciting drug-development space \xe2\x80\x93 advancing novel targeted therapies against KRAS and TRAILR2,\xe2\x80\x9d said Timothy Heffernan, Ph.D., Head of Oncology Research in Therapeutics Discovery at MD Anderson.
  • No approved treatments for KRAS-driven cancers exist currently, further underscoring the need for continued investment in research and development.

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Retrieved on: 
Tuesday, April 13, 2021
Health, Diabetes, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Boehringer Ingelheim, Obesity, Zealand Pharma, Boehringer, Economy of Germany, Clinical medicine, Health

The compound was in-licensed from Zealand in 2011 and is being investigated in an ongoing Phase 2 study in people with type 2 diabetes mellitus.

Key Points: 
  • The compound was in-licensed from Zealand in 2011 and is being investigated in an ongoing Phase 2 study in people with type 2 diabetes mellitus.
  • BI 456906 is part of Boehringer Ingelheim\xe2\x80\x99s growing portfolio in the obesity and NASH disease areas.\n\xe2\x80\x9cObesity and NASH are areas of high unmet medical need, with limited approved treatments currently available.
  • \xe2\x80\x9cWe are very excited to see the initiation of Phase 2 trials of BI 456906 for obesity and NASH,\xe2\x80\x9d said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma.
  • \xe2\x80\x9cWe are exploring a number of unique approaches with great potential to help people living with obesity or NASH.

Click Therapeutics Expands its Leadership with Executive and Board Appointments

Retrieved on: 
Wednesday, April 7, 2021
Other Health, Software, Managed care, Mobile, Wireless, General Health, Pharmaceutical, Data management, Mental health, Technology, Biotechnology, Alternative medicine, Health, Boehringer Ingelheim, Boehringer, Economy of Germany, Germany, Companies

Wall Street veteran Randall Stanicky has joined the company leadership as Chief Financial Officer; accomplished digital healthcare executive Lee Shapiro has joined the Board of Directors; and former biopharmaceutical executive Muzammil Mansuri, Ph.D. has expanded his role at Click through appointment as Board Chair.

Key Points: 
  • Wall Street veteran Randall Stanicky has joined the company leadership as Chief Financial Officer; accomplished digital healthcare executive Lee Shapiro has joined the Board of Directors; and former biopharmaceutical executive Muzammil Mansuri, Ph.D. has expanded his role at Click through appointment as Board Chair.
  • We are honored to have these industry experts on the Click team, said David Benshoof Klein, co-founder and CEO of Click Therapeutics.
  • "The transformative potential of digital therapeutics and the breadth of Click's platform is what drew me to the company," said Stanicky.
  • The executive leadership and Board announcements follow Clicks strategic partnerships with Otsuka, Boehringer Ingelheim, and a variety of payers, employers, and thought leaders.

Wind Energy Powers Boehringer Ingelheim's Largest U.S. Manufacturing Site

Retrieved on: 
Tuesday, April 6, 2021
Boehringer Ingelheim, Pharmaceutical companies, Boehringer, Ingelheim am Rhein, Carbon neutrality, Economy of Germany, States of Germany

Wind energy now provides all electricity used at the site, where Boehringer Ingelheim employs nearly 1,000 people who manufacture vaccines for horses, pigs, cattle and other animals.

Key Points: 
  • Wind energy now provides all electricity used at the site, where Boehringer Ingelheim employs nearly 1,000 people who manufacture vaccines for horses, pigs, cattle and other animals.
  • In North Brunswick, N.J., a Boehringer Ingelheim Animal Health research and development site has transitioned to renewable energy by purchasing green power.
  • A poultry-vaccine manufacturing plant in Gainesville, Ga., is on pace to become Boehringer Ingelheim's first major U.S. production site to go carbon neutral.
  • Boehringer Ingelheim's U.S. headquarters in Ridgefield, Conn., which employs about 2,500 people, transitioned to renewable energy last year.

Boehringer Ingelheim to Work with Xybion's Preclinical Gold Standard Solution, Pristima XD, to Enhance Lab Operations

Retrieved on: 
Monday, March 29, 2021
Drug discovery, Pharmaceutical industry, Boehringer Ingelheim, Good laboratory practice, Preclinical development, Workflow, Boehringer, Ingelheim am Rhein, Health sciences, Pharmacology, Economy of Germany

PRINCETON, N.J., March 29, 2021 /PRNewswire/ --Xybion Corporation announced today it is partnering with Boehringer Ingelheim to enhance process efficiency and data integrity in the Preclinical lab.

Key Points: 
  • PRINCETON, N.J., March 29, 2021 /PRNewswire/ --Xybion Corporation announced today it is partnering with Boehringer Ingelheim to enhance process efficiency and data integrity in the Preclinical lab.
  • This end to end preclinical gold standard solution helps with study planning, protocol, study execution, animal management, data management and regulatory submissions globally.
  • The preclinical lab processes and data management are a critical part of Boehringer Ingelheim's development, and the enhanced processes will make Good Laboratory Practice (GLP) as well as non-GLP studies more efficient.
  • Xybion's Pristima XD gold standard preclinical solution creates an end-to-end digital laboratory execution environment with connected workflows, innovative technology-driven automation, integrated instruments, and data management for the entire preclinical operation."

Boehringer Ingelheim Makes Rapid Shift to Digital Engagement with Veeva CRM Engage Meeting

Retrieved on: 
Wednesday, March 24, 2021
Other Health, Software, Networks, General Health, Internet, Pharmaceutical, Data management, Technology, Audio, Video, Other Technology, Telecommunications, Health, Veeva Systems, Boehringer, Companies, Computer companies, Industry economics)

Boehringer Ingelheim , a top 20 global pharmaceutical company, is standardizing on Veeva CRM Engage Meeting to drive more valued interactions between its global field organization and healthcare providers (HCPs).

Key Points: 
  • Boehringer Ingelheim , a top 20 global pharmaceutical company, is standardizing on Veeva CRM Engage Meeting to drive more valued interactions between its global field organization and healthcare providers (HCPs).
  • The companys adoption of Veeva CRM Engage Meeting builds upon its success using Veeva CRM for multichannel engagement, including Veeva CRM Approved Email , Veeva Events , and Veeva Align .
  • Boehringer Ingelheim also uses Veeva Vault PromoMats and Veeva Vault MedComms to more quickly create compliant digital content that field teams use during engagements with HCPs.
  • For more on Veeva CRM Engage Meeting, visit: veeva.com/EngageMeeting
    Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
    Veeva is the global leader in cloud software for the life sciences industry.